S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
His system isolated NVIDIA - Here's His Next Buy. (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
The single greatest medical breakthrough of all time? (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
His system isolated NVIDIA - Here's His Next Buy. (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
The single greatest medical breakthrough of all time? (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
His system isolated NVIDIA - Here's His Next Buy. (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
The single greatest medical breakthrough of all time? (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
His system isolated NVIDIA - Here's His Next Buy. (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
The single greatest medical breakthrough of all time? (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
NASDAQ:BPTH

Bio-Path (BPTH) Stock Forecast, Price & News

$0.37
0.00 (0.00%)
(As of 09/29/2023 ET)
Compare
Today's Range
$0.36
$0.40
50-Day Range
$0.36
$1.09
52-Week Range
$0.35
$3.54
Volume
92,393 shs
Average Volume
56,575 shs
Market Capitalization
$4.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Bio-Path MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.89% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.30mentions of Bio-Path in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.70) to ($1.28) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.22 out of 5 stars


BPTH stock logo

About Bio-Path (NASDAQ:BPTH) Stock

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 (BP1002) for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 (BP1003) for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and BP1001-A for the treatment of solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

BPTH Price History

BPTH Stock News Headlines

Bio-Path (NASDAQ:BPTH) Now Covered by StockNews.com
Better Than Oil Stocks?
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.
Bio-Path Holdings, Inc.'s (NASDAQ:BPTH) Profit Outlook
The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult. And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Bio-Path Holdings's Earnings Outlook
Why Bio-Path Holdings (BPTH) Stock Is Down 45%
Bio-Path Holdings Earnings Preview
8-K: BIO-PATH HOLDINGS INC
See More Headlines
Receive BPTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Path and its competitors with MarketBeat's FREE daily newsletter.

BPTH Company Calendar

Last Earnings
8/15/2023
Today
9/30/2023
Next Earnings (Estimated)
11/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BPTH
Fax
N/A
Employees
10
Year Founded
2007

Profitability

Net Income
$-13,870,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.98 per share

Miscellaneous

Free Float
11,054,000
Market Cap
$4.24 million
Optionable
Not Optionable
Beta
1.36

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Peter H. Nielsen MBA (Age 74)
    Co-Founder, Chairman, CEO, Pres, CFO & Treasurer
    Comp: $722.68k
  • Mr. Douglas P. Morris (Age 67)
    Co-Founder, Director of Investor Relations, Sec. & Director
    Comp: $110.68k
  • Mr. Anthony Price
    Sr. VP of Fin., Accounting & Admin.
  • Dr. Ana Tari Ashizawa Ph.D.
    MBA, Sr. VP of Research, Devel. & Clinical Design













BPTH Stock - Frequently Asked Questions

Should I buy or sell Bio-Path stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Path in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BPTH shares.
View BPTH analyst ratings
or view top-rated stocks.

How have BPTH shares performed in 2023?

Bio-Path's stock was trading at $1.51 at the beginning of the year. Since then, BPTH stock has decreased by 75.5% and is now trading at $0.37.
View the best growth stocks for 2023 here
.

Are investors shorting Bio-Path?

Bio-Path saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 216,700 shares, an increase of 23.1% from the August 31st total of 176,000 shares. Based on an average daily volume of 340,600 shares, the short-interest ratio is presently 0.6 days.
View Bio-Path's Short Interest
.

When is Bio-Path's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 21st 2023.
View our BPTH earnings forecast
.

How were Bio-Path's earnings last quarter?

Bio-Path Holdings, Inc. (NASDAQ:BPTH) posted its quarterly earnings results on Tuesday, August, 15th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by $0.01. During the same period in the previous year, the firm posted ($0.42) EPS.

When did Bio-Path's stock split?

Bio-Path shares reverse split on Friday, January 18th 2019. The 1-20 reverse split was announced on Friday, January 18th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 17th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Bio-Path own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Path investors own include NVIDIA (NVDA), Palatin Technologies (PTN), Micron Technology (MU), Advanced Micro Devices (AMD), Amarin (AMRN), Trevena (TRVN), Energy Transfer (ET), Anavex Life Sciences (AVXL) and Biocept (BIOC).

What is Bio-Path's stock symbol?

Bio-Path trades on the NASDAQ under the ticker symbol "BPTH."

How do I buy shares of Bio-Path?

Shares of BPTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bio-Path's stock price today?

One share of BPTH stock can currently be purchased for approximately $0.37.

How much money does Bio-Path make?

Bio-Path (NASDAQ:BPTH) has a market capitalization of $4.24 million. The company earns $-13,870,000.00 in net income (profit) each year or ($2.21) on an earnings per share basis.

How can I contact Bio-Path?

Bio-Path's mailing address is 4710 BELLAIRE BOULEVARD SUITE 210, BELLAIRE TX, 77401. The official website for the company is www.biopathholdings.com. The company can be reached via phone at (832) 742-1357 or via email at will@sternir.com.

This page (NASDAQ:BPTH) was last updated on 9/30/2023 by MarketBeat.com Staff

My Account -